Hangzhou Fuluo Biological Technology Co.,Ltd.
High quality, competitive price, fast delivery
Payment & Shipping Terms:
|Molecular Formula::||C14H22N2O||Molecular Weight::||234.34|
|Purity::||99%||Appearance: Trans:||Colorless To Pale Yellow Transparent Liquid|
|Grade ::||Pharmaceutical Grade|
CAS 137-58-6 Lidocaine
CAS Registry Number:137-58-6
Appearance:White Crystalline Powder
Lidocaine,xylocaine, or lignocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or used as a local anesthetic for minor surgery.
The efficacy profile of lidocaine as a local anesthetic is characterized by a rapid onset of action and intermediate duration of efficacy. Therefore, lidocaine is suitable for infiltration, block, and surface anesthesia. Longer-acting substances such as bupivacaine are sometimes given preference for subdural and epidural anesthesias; lidocaine, though, has the advantage of a rapid onset of action. Epinephrine (adrenaline) vasoconstricts arteries, reducing bleeding and also delays the resorption of lidocaine, almost doubling the duration of anaesthesia. For surface anesthesia, several available formulations can be used for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local freezing less painful.Lidocaine drops can be used on the eyes for short ophthalmic procedures.
There is tentative evidence for topical lidocaine for neuropathic pain.Intravenous lidocaine also has uses as a temporary fix for tinnitus. Although not completely curing the disorder, it has been shown to reduce the effects by around two-thirds.
Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine prophylactic administration is no longer recommended for acute cardiac infarction; the overall benefit of this measure is not convincing.